United Kingdom · Question · Written question
UIN 16975
Tixagevimab/cilgavimab
Original
Introduced
13 June 2022
Last action
21 June 2022 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
21 June 2022
Summary
To ask the Secretary of State for Health and Social Care, what his planned timetable is for making a decision on the use of Evusheld following conclusion of UKHSA testing.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
13 June 2022
Written question
To ask the Secretary of State for Health and Social Care, what his planned timetable is for making a decision on the use of Evusheld following conclusion of UKHSA testing.
Source: Commons
21 June 2022
Answer
AstraZeneca commissioned the UK Health Strategic Authority to conduct studies into the effectiveness of Evusheld against the Omicron variants. Initial data has been shared with AstraZeneca. The Department is also assessing Evusheld through requesting advi...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2022-06-13/16975
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1469727
- uk · wq-1469727 · source updated 21 June 2022